US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ZyVersa Therapeutics, Inc.

0.1846

-0.1267-40.70%

Volume:1.71M

Turnover:332.88K

Market Cap:899.64K

PE:-0.02

High:0.2520

Open:0.1546

Low:0.1546

Close:0.3113

Loading ...

Overview Company News Filings

Zyversa Therapeutics Faces Nasdaq Delisting Due to Failure to Meet Minimum Bid Price Requirements

Zyversa Therapeutics Inc. Enters Warrant Exercise Inducement Agreement for 3.06M Shares, Plans to Register Inducement Warrant Shares

ZyVersa announces warrant inducement transaction for $2M in gross proceeds

ZyVersa supports FDA-authorized Emergency Compassionate Use of VAR 200

ZyVersa announces first clinical site activation in VAR 200 Phase 2a trial

Zyversa Therapeutics Inc - Preliminary Data Expected in H2-2025, Final Results in H2-2026

THOMSON REUTERS

Zyversa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediator™ Var 200’S Phase 2a Clinical Trial in Patients With Diabetic Kidney Disease (Dkd)

THOMSON REUTERS

ZyVersa Therapeutics Initiates New Clinical Study for Cholesterol Efflux Mediator VAR 200 to Combat Chronic Kidney Diseases

BRIEF-ZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million

Zyversa Therapeutics Announces Share Purchase Agreement for up to $10 Million in Partnership With Williamsburg Venture Holdings to Fund Clinical Development of Cholesterol Efflux Mediator™ Var 200

THOMSON REUTERS

Zyversa Therapeutics Inc. Conducted Annual Stockholders Meeting

Zyversa Therapeutics Faces Potential Nasdaq Delisting Due to Bid Price Non-Compliance

Press Release: ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress

BRIEF-ZyVersa Unveils Potential Of Inflammasome Inhibitors In Combination With GLP-1 Agonists To Address Needs Of People Living With Obesity

Zyversa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination With Glp-1 Agonists to Address Unmet Medical Needs of People Living With Obesity; Provides R&D Update

THOMSON REUTERS

BRIEF-Zyversa Therapeutics Announces Published Data Showing Inflammasome Asc Inhibitor IC 100 Decreases Microglial Inflammasome Activation

Zyversa Therapeutics Announces Published Data Showing Inflammasome Asc Inhibitor Ic 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkinson’s Disease

THOMSON REUTERS

ZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkinson’s Disease

BRIEF-ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative Research And Development Trends For Inflammasome Inhibitors, And Provides Update On Inflammasome ASC Inhibitor IC 100’S Development Status

Zyversa Therapeutics CEO Issues Shareholder Letter on Parasol Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (Fsgs)

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ZVSA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ZVSA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ZVSA\",,,,,undefined,":{"symbol":"ZVSA","market":"US","secType":"STK","nameCN":"ZyVersa Therapeutics, Inc.","latestPrice":0.1846,"timestamp":1752782400000,"preClose":0.3113,"halted":0,"volume":1705838,"delay":15,"floatShares":3613500,"shares":4873463,"eps":-8.480319,"marketStatus":"Closed","change":-0.1267,"latestTime":"07-17 16:00:00 EDT Delay","open":0.1546,"high":0.252,"low":0.1546,"amount":332879.6305399998,"amplitude":0.312881,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-8.480319,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1752825600000},"marketStatusCode":5,"adr":0,"exchange":"PINK LIMITED","adjPreClose":0.3113,"volumeRatio":0.516475},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ZVSA\",,,,,undefined,":{"symbol":"ZVSA","floatShares":3613500,"roa":"-24.79%","roe":"-91.39%","lyrEps":-8.480319,"volumeRatio":0.516475,"shares":4873463,"dividePrice":0,"high":0.252,"amplitude":0.312881,"preClose":0.3113,"low":0.1546,"week52Low":0.1546,"pbRate":"0.11","week52High":5.22,"institutionHeld":0,"latestPrice":0.1846,"eps":-8.480319,"divideRate":0,"volume":1705838,"delay":15,"ttmEps":-8.480319,"open":0.1546,"prevYearClose":0.3113,"fiveDayClose":0.3113,"twentyDayClose":0.3113,"sixtyDayClose":0.3113},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ZVSA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2552124745","title":"Zyversa Therapeutics Faces Nasdaq Delisting Due to Failure to Meet Minimum Bid Price Requirements","url":"https://stock-news.laohu8.com/highlight/detail?id=2552124745","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552124745?lang=en_us&edition=fundamental","pubTime":"2025-07-17 00:41","pubTimestamp":1752684084,"startTime":"0","endTime":"0","summary":"ZyVersa Therapeutics Inc. has announced that it received a determination letter from The Nasdaq Stock Market LLC indicating the denial of its request to continue listing on The Nasdaq Capital Market. This decision follows the company's non-compliance with the minimum bid price requirements under Nasdaq's Listing Rule 5550. Despite appealing the decision and requesting an exception to complete its compliance plan, the Nasdaq Hearings Panel upheld the delisting decision. Consequently, trading of ZyVersa's common stock will be suspended at the opening of trading on July 17, 2025. The company plans to mitigate the impact by applying for trading on the Pink Limited Market under the symbol \"ZVSA.\" This move might pose challenges for stockholders due to a potentially limited market for trading shares.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250716:nNDLKjgSw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZVSA"],"gpt_icon":0},{"id":"2550966335","title":"Zyversa Therapeutics Inc. Enters Warrant Exercise Inducement Agreement for 3.06M Shares, Plans to Register Inducement Warrant Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2550966335","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550966335?lang=en_us&edition=fundamental","pubTime":"2025-07-10 04:16","pubTimestamp":1752092184,"startTime":"0","endTime":"0","summary":"Zyversa Therapeutics Inc. Enters Warrant Exercise Inducement Agreement for 3.06M Shares, Plans to Register Inducement Warrant Shares. On July 8, 2025, Zyversa Therapeutics Inc. entered into a warrant exercise inducement offer agreement with a holder of Series A-2 and A-3 Common Stock purchase warrants. The holder agreed to exercise the existing warrants, originally issued on November 5, 2024, and March 5, 2025, for a reduced price of $0.67 per share, down from $1.00. This involves up to 957,200 shares from Series A-2 Warrants and 2,105,265 shares from Series A-3 Warrants. Zyversa will issue new Series A-4 warrants for up to 6,124,930 shares at $0.67 each, exercisable over five years from the stockholder approval date.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250709:nNDL6qyKYm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZVSA","BK4139"],"gpt_icon":0},{"id":"2550494524","title":"ZyVersa announces warrant inducement transaction for $2M in gross proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=2550494524","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550494524?lang=en_us&edition=fundamental","pubTime":"2025-07-09 00:35","pubTimestamp":1751992517,"startTime":"0","endTime":"0","summary":"ZyVersa Therapeutics (ZVSA) announced its entry into a warrant inducement agreement with a single institutional investor of the company. Terms of t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zyversa-announces-warrant-inducement-transaction-for-2m-in-gross-proceeds-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zyversa-announces-warrant-inducement-transaction-for-2m-in-gross-proceeds-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZVSA","BK4139"],"gpt_icon":0},{"id":"2549791544","title":"ZyVersa supports FDA-authorized Emergency Compassionate Use of VAR 200","url":"https://stock-news.laohu8.com/highlight/detail?id=2549791544","media":"TIPRANKS","labels":["policyRegulatory","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549791544?lang=en_us&edition=fundamental","pubTime":"2025-07-08 19:55","pubTimestamp":1751975712,"startTime":"0","endTime":"0","summary":"ZyVersa Therapeutics (ZVSA) provided regulatory and product support for FDA-authorized Emergency Compassionate Use of Cholesterol Efflux Mediator V...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zyversa-supports-fda-authorized-emergency-compassionate-use-of-var-200-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zyversa-supports-fda-authorized-emergency-compassionate-use-of-var-200-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ZVSA"],"gpt_icon":0},{"id":"2546955780","title":"ZyVersa announces first clinical site activation in VAR 200 Phase 2a trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2546955780","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546955780?lang=en_us&edition=fundamental","pubTime":"2025-06-26 20:00","pubTimestamp":1750939258,"startTime":"0","endTime":"0","summary":"ZyVersa Therapeutics (ZVSA) announces that the Clinical Advancement Center, PLLC in San Antonio, Texas is the first clinical site activated and rea...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zyversa-announces-first-clinical-site-activation-in-var-200-phase-2a-trial-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zyversa-announces-first-clinical-site-activation-in-var-200-phase-2a-trial-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ZVSA"],"gpt_icon":0},{"id":"2546787791","title":"Zyversa Therapeutics Inc - Preliminary Data Expected in H2-2025, Final Results in H2-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2546787791","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546787791?lang=en_us&edition=fundamental","pubTime":"2025-06-26 19:55","pubTimestamp":1750938900,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nTUA7D9MBL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ZVSA"],"gpt_icon":0},{"id":"2546787759","title":"Zyversa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediator™ Var 200’S Phase 2a Clinical Trial in Patients With Diabetic Kidney Disease (Dkd)","url":"https://stock-news.laohu8.com/highlight/detail?id=2546787759","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546787759?lang=en_us&edition=fundamental","pubTime":"2025-06-26 19:55","pubTimestamp":1750938900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nTUA7D9MBL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ZVSA"],"gpt_icon":0},{"id":"2546248130","title":"ZyVersa Therapeutics Initiates New Clinical Study for Cholesterol Efflux Mediator VAR 200 to Combat Chronic Kidney Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2546248130","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546248130?lang=en_us&edition=fundamental","pubTime":"2025-06-25 21:01","pubTimestamp":1750856501,"startTime":"0","endTime":"0","summary":"ZyVersa Therapeutics Inc., a clinical stage specialty biopharmaceutical company, has announced a share purchase agreement with Williamsburg Venture Holdings to fund the clinical development of their Cholesterol Efflux MediatorTM VAR 200 for treating chronic kidney diseases. The agreement allows ZyVersa to sell up to $10 million worth of common stock over a 24-month period, with Williamsburg Venture Holdings obligated to purchase these shares at a discounted market price. This partnership aims to provide ZyVersa with a flexible source of funding to advance the clinical development of VAR 200. The company plans to use the share purchase agreement strategically to achieve key development milestones while minimizing shareholder dilution. There are no warrants or derivatives associated with the agreement, and ZyVersa retains control over the timing and amount of stock sales. The results of the clinical development are not yet presented.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nNDL73MfvV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZVSA"],"gpt_icon":0},{"id":"2546212048","title":"BRIEF-ZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2546212048","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546212048?lang=en_us&edition=fundamental","pubTime":"2025-06-25 19:56","pubTimestamp":1750852591,"startTime":"0","endTime":"0","summary":"BRIEF-ZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 MillionJune 25 (Reuters) - Zyversa Therapeutics Inc ZVSA.O:ZYVERSA THERAPEUTICS ANNOUNCES SHARE PURCHASE AGREEMENT FOR UP TO","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nTUABQ5XPK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZVSA","BK4139"],"gpt_icon":0},{"id":"2546052212","title":"Zyversa Therapeutics Announces Share Purchase Agreement for up to $10 Million in Partnership With Williamsburg Venture Holdings to Fund Clinical Development of Cholesterol Efflux Mediator™ Var 200","url":"https://stock-news.laohu8.com/highlight/detail?id=2546052212","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546052212?lang=en_us&edition=fundamental","pubTime":"2025-06-25 19:55","pubTimestamp":1750852500,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nTUABQ5XPK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ZVSA"],"gpt_icon":0},{"id":"2543419547","title":"Zyversa Therapeutics Inc. Conducted Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2543419547","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543419547?lang=en_us&edition=fundamental","pubTime":"2025-06-13 04:47","pubTimestamp":1749761272,"startTime":"0","endTime":"0","summary":"Zyversa Therapeutics Inc. held its annual meeting of stockholders on June 11, 2025. During the meeting, stockholders elected Stephen C. Glover and Robert G. Finizio as Class III directors. Additionally, stockholders ratified the selection of CBIZ CPAs, P.C. as the independent registered public accounting firm for the year ending December 31, 2025. The Amended and Restated Equity Incentive Plan, which increases the number of shares of common stock reserved for issuance, was also approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zyversa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchan","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250612:nNDL89VYvz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZVSA"],"gpt_icon":0},{"id":"2539270274","title":"Zyversa Therapeutics Faces Potential Nasdaq Delisting Due to Bid Price Non-Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2539270274","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539270274?lang=en_us&edition=fundamental","pubTime":"2025-05-31 04:16","pubTimestamp":1748636180,"startTime":"0","endTime":"0","summary":"Zyversa Therapeutics Inc. has announced it received a Minimum Bid Price Deficiency Letter from The Nasdaq Capital Market Stock Exchange on May 27, 2025. The notice indicates the company's common stock had a closing bid price below $1.00 for 30 consecutive business days, placing it in non-compliance with Listing Rule 5550. Typically, companies have a 180-day period to regain compliance; however, Zyversa is not eligible for this due to two reverse stock splits within the past two years, including a 1-for-35 reverse split in December 2023 and a 1-for-10 reverse split in April 2024. Zyversa plans to appeal the decision and request a hearing before a panel, which will temporarily halt any suspension or delisting actions pending the panel's decision. The company must submit its appeal by June 3, 2025, to prevent its securities from being delisted on June 5, 2025. There is no guarantee that Zyversa will meet the necessary requirements for continued listing on the Nasdaq Capital Market.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nNDL5drM9w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZVSA","BK4139"],"gpt_icon":0},{"id":"2535178443","title":"Press Release: ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2535178443","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535178443?lang=en_us&edition=fundamental","pubTime":"2025-05-13 04:35","pubTimestamp":1747082100,"startTime":"0","endTime":"0","summary":"-- First patient expected to start therapy by end of Q2-2025 in Phase 2a. proof-of concept clinical trial for Cholesterol Efflux MediatorTM VAR 200. with Inflammasome ASC Inhibitor IC 100 planned to begin by end of. -- Investigational New Drug Application  for IC 100 anticipated to be. submitted H2-2025, followed by initiation of a Phase 1 clinical trial in. healthy overweight subjects at risk of cardiometabolic diseases.-- Groundbreaking data demonstrating IC 100 blocks microglial inflammasome. activation and reduces neurotoxic alpha-synuclein accumulation -- both. progression -- recently published (study sponsored by Michael J. Fox. -- Invited MJFF grant request submitted for funding PD animal model. WESTON, Fla., May 12, 2025  -- ZyVersa Therapeutics, Inc. , a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of renal and inflammatory diseases with high unmet medical needs, reports financial results for the quarter ended March 31, 2","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZVSA","BK4604","BK4555","PRGS","LU2065732104.USD","BK4585","BK4539","BK4588","BK4099","BK4007","03160","LENZ","PD","BK4023","BK4139","TM","LU1169589451.USD","LU1169590202.USD","BK4097"],"gpt_icon":0},{"id":"2533984508","title":"BRIEF-ZyVersa Unveils Potential Of Inflammasome Inhibitors In Combination With GLP-1 Agonists To Address Needs Of People Living With Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2533984508","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533984508?lang=en_us&edition=fundamental","pubTime":"2025-05-07 19:59","pubTimestamp":1746619172,"startTime":"0","endTime":"0","summary":"BRIEF-ZyVersa Unveils Potential Of Inflammasome Inhibitors In Combination With GLP-1 Agonists To Address Needs Of People Living With Obesity May 7 (Reuters) - Zyversa Therapeutics Inc ZVSA.O:ZYVERSA U","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250507:nTUA4RSY26:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZVSA","BK4139"],"gpt_icon":0},{"id":"2533981206","title":"Zyversa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination With Glp-1 Agonists to Address Unmet Medical Needs of People Living With Obesity; Provides R&D Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2533981206","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533981206?lang=en_us&edition=fundamental","pubTime":"2025-05-07 19:57","pubTimestamp":1746619020,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250507:nTUA4RSY26:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ZVSA"],"gpt_icon":0},{"id":"2531739814","title":"BRIEF-Zyversa Therapeutics Announces Published Data Showing Inflammasome Asc Inhibitor IC 100 Decreases Microglial Inflammasome Activation","url":"https://stock-news.laohu8.com/highlight/detail?id=2531739814","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531739814?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:50","pubTimestamp":1745931028,"startTime":"0","endTime":"0","summary":"BRIEF-Zyversa Therapeutics Announces Published Data Showing Inflammasome Asc Inhibitor IC 100 Decreases Microglial Inflammasome Activation April 29 (Reuters) - Zyversa Therapeutics Inc ZVSA.O:ZYVERSA ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nTUA12JXSK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZVSA"],"gpt_icon":0},{"id":"2531873597","title":"Zyversa Therapeutics Announces Published Data Showing Inflammasome Asc Inhibitor Ic 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkinson’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2531873597","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531873597?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:57","pubTimestamp":1745927820,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nTUA12JXSK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ZVSA"],"gpt_icon":0},{"id":"2531801387","title":"ZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkinson’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2531801387","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531801387?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:57","pubTimestamp":1745927820,"startTime":"0","endTime":"0","summary":"Study supported by the Michael J. Fox Foundation through a grant awarded to ZyVersa and leading inflammasome experts at University of Miami Miller School of Medicine who conducted the study.Parkinson’s Disease  affects over 10 million people globally and is driven by inflammation leading to progressive neurodegeneration resulting in impaired mobility, cognitive decline, and other neurological symptoms.WESTON, Fla., April 29, 2025  -- ZyVersa Therapeutics, Inc. , a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, announces newly published data supporting the potential of its Inflammasome ASC Inhibitor IC 100 to slow the progression of Parkinson’s disease.Published in npj Parkinson's Disease, a peer-reviewed journal from Nature, the study presents groundbreaking findings from researchers at the University of Miami Miller School of Medicine. The research demonstrates that IC 100 blocks microglial inflammas","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zyversa-therapeutics-announces-published-data-115700776.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4144","LU1169590202.USD","ZVSA","BK4023","BK4007","LU1169589451.USD","ASC","FSGS","PD","LENZ"],"gpt_icon":0},{"id":"2529816929","title":"BRIEF-ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative Research And Development Trends For Inflammasome Inhibitors, And Provides Update On Inflammasome ASC Inhibitor IC 100’S Development Status","url":"https://stock-news.laohu8.com/highlight/detail?id=2529816929","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529816929?lang=en_us&edition=fundamental","pubTime":"2025-04-24 20:26","pubTimestamp":1745497586,"startTime":"0","endTime":"0","summary":"BRIEF-ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative Research And Development Trends For Inflammasome Inhibitors, And Provides Update On Inflammasome ASC Inhibitor IC 100","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250424:nTUA836CC1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZVSA","BK4139"],"gpt_icon":0},{"id":"2525896963","title":"Zyversa Therapeutics CEO Issues Shareholder Letter on Parasol Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (Fsgs)","url":"https://stock-news.laohu8.com/highlight/detail?id=2525896963","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525896963?lang=en_us&edition=fundamental","pubTime":"2025-04-08 19:57","pubTimestamp":1744113434,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM0TT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ZVSA"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":29,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ZVSA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-07-17","symbol":"ZVSA","reason":null,"defaultRemindTime":1752759000000,"announcedDate":"2025-07-16","type":"delisting","dateTimestamp":1752724800000},{"market":"US","date":"2025-05-12","symbol":"ZVSA","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747022400000,"reportTimeType":"post","actualEps":-0.73},{"date":"2025-03-27","symbol":"ZVSA","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1743062400000,"name":null,"time":"Pre-Market","dateTimestamp":1743048000000,"actualEps":null},{"market":"US","date":"2024-11-14","symbol":"ZVSA","fiscalQuarterEnding":"2024/09","expectedEps":-5.8,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"pre","actualEps":-2.43},{"market":"US","date":"2024-08-09","symbol":"ZVSA","fiscalQuarterEnding":"2024/06","expectedEps":-5.2,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723176000000,"reportTimeType":"post","actualEps":-3.31}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ZVSA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ZVSA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ZVSA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ZVSA","date":"2025-07-16","current":-0.302538,"percent":0.481258,"low":-21.281928,"twenty":-7.733869,"median":-0.246413,"eighty":-0.055543,"high":-0.009885,"avg":-2.550237,"sd":3.834209,"marketCap":2675531},"quantilePoints":[{"date":"2022-02-11","current":-7.527467,"twenty":-7.527467,"median":-7.527467,"eighty":-7.527467,"marketCap":95472110},{"date":"2022-02-18","current":-7.542751,"twenty":-7.542751,"median":-7.542751,"eighty":-7.527467,"marketCap":95665962},{"date":"2022-02-25","current":-7.542751,"twenty":-7.542751,"median":-7.542751,"eighty":-7.527467,"marketCap":95665962},{"date":"2022-03-04","current":-7.535109,"twenty":-7.542751,"median":-7.542751,"eighty":-7.535109,"marketCap":95569036},{"date":"2022-03-11","current":-7.550393,"twenty":-7.542751,"median":-7.542751,"eighty":-7.535109,"marketCap":95762888},{"date":"2022-03-18","current":-7.565677,"twenty":-7.550393,"median":-7.542751,"eighty":-7.535109,"marketCap":95956740},{"date":"2022-03-25","current":-7.603888,"twenty":-7.550393,"median":-7.542751,"eighty":-7.542751,"marketCap":96441370},{"date":"2022-04-01","current":-7.603888,"twenty":-7.565677,"median":-7.550393,"eighty":-7.542751,"marketCap":96441370},{"date":"2022-04-08","current":-7.603888,"twenty":-7.603888,"median":-7.550393,"eighty":-7.542751,"marketCap":96441370},{"date":"2022-04-14","current":-7.603888,"twenty":-7.603888,"median":-7.550393,"eighty":-7.542751,"marketCap":96441370},{"date":"2022-04-22","current":-7.852153,"twenty":-7.603888,"median":-7.558035,"eighty":-7.542751,"marketCap":99590164},{"date":"2022-04-29","current":-7.860061,"twenty":-7.603888,"median":-7.565677,"eighty":-7.542751,"marketCap":99690456},{"date":"2022-05-06","current":-7.867968,"twenty":-7.860061,"median":-7.603888,"eighty":-7.542751,"marketCap":99790748},{"date":"2022-05-13","current":-7.836338,"twenty":-7.860061,"median":-7.603888,"eighty":-7.542751,"marketCap":99389580},{"date":"2022-05-20","current":-7.875876,"twenty":-7.860061,"median":-7.603888,"eighty":-7.542751,"marketCap":99891041},{"date":"2022-05-27","current":-7.852153,"twenty":-7.860061,"median":-7.603888,"eighty":-7.542751,"marketCap":99590164},{"date":"2022-06-03","current":-7.875876,"twenty":-7.860061,"median":-7.603888,"eighty":-7.542751,"marketCap":99891041},{"date":"2022-06-10","current":-7.875876,"twenty":-7.867968,"median":-7.603888,"eighty":-7.547336,"marketCap":99891041},{"date":"2022-06-17","current":-7.836338,"twenty":-7.867968,"median":-7.603888,"eighty":-7.550393,"marketCap":99389580},{"date":"2022-06-24","current":-7.875876,"twenty":-7.867968,"median":-7.820523,"eighty":-7.550393,"marketCap":99891041},{"date":"2022-07-01","current":-7.836338,"twenty":-7.867968,"median":-7.836338,"eighty":-7.550393,"marketCap":99389580},{"date":"2022-07-08","current":-7.860061,"twenty":-7.867968,"median":-7.836338,"eighty":-7.550393,"marketCap":99690456},{"date":"2022-07-15","current":-7.875876,"twenty":-7.867968,"median":-7.844246,"eighty":-7.550393,"marketCap":99891041},{"date":"2022-07-22","current":-7.875876,"twenty":-7.874294,"median":-7.844246,"eighty":-7.550393,"marketCap":99891041},{"date":"2022-07-29","current":-7.875876,"twenty":-7.875876,"median":-7.850967,"eighty":-7.550393,"marketCap":99891041},{"date":"2022-08-05","current":-7.891691,"twenty":-7.875876,"median":-7.852153,"eighty":-7.55345,"marketCap":100091625},{"date":"2022-08-12","current":-10.347355,"twenty":-7.875876,"median":-7.852153,"eighty":-7.565677,"marketCap":100292210},{"date":"2022-08-19","current":-10.337007,"twenty":-7.875876,"median":-7.852153,"eighty":-7.565677,"marketCap":100191917},{"date":"2022-08-26","current":-10.337007,"twenty":-7.875876,"median":-7.852153,"eighty":-7.565677,"marketCap":100191917},{"date":"2022-09-02","current":-10.32666,"twenty":-7.875876,"median":-7.852153,"eighty":-7.573319,"marketCap":100091625},{"date":"2022-09-09","current":-10.347355,"twenty":-7.883783,"median":-7.860061,"eighty":-7.603888,"marketCap":100292210},{"date":"2022-09-16","current":-10.316312,"twenty":-7.891691,"median":-7.860061,"eighty":-7.603888,"marketCap":99991333},{"date":"2022-09-23","current":-10.357702,"twenty":-7.907506,"median":-7.860061,"eighty":-7.603888,"marketCap":100392502},{"date":"2022-09-30","current":-10.434782,"twenty":-10.316312,"median":-7.860061,"eighty":-7.603888,"marketCap":100191917},{"date":"2022-10-07","current":-10.445227,"twenty":-10.32666,"median":-7.860061,"eighty":-7.603888,"marketCap":100292210},{"date":"2022-10-14","current":-10.476563,"twenty":-10.32666,"median":-7.867968,"eighty":-7.603888,"marketCap":100593086},{"date":"2022-10-21","current":-10.497453,"twenty":-10.337007,"median":-7.867968,"eighty":-7.603888,"marketCap":100793671},{"date":"2022-10-28","current":-10.476563,"twenty":-10.337007,"median":-7.875876,"eighty":-7.603888,"marketCap":100593086},{"date":"2022-11-04","current":-10.507899,"twenty":-10.347355,"median":-7.875876,"eighty":-7.603888,"marketCap":100893963},{"date":"2022-11-11","current":-10.539234,"twenty":-10.357702,"median":-7.875876,"eighty":-7.603888,"marketCap":101194839},{"date":"2022-11-18","current":-10.586238,"twenty":-10.378397,"median":-7.875876,"eighty":-7.603888,"marketCap":101646154},{"date":"2022-11-25","current":-10.643686,"twenty":-10.434782,"median":-7.875876,"eighty":-7.603888,"marketCap":102197761},{"date":"2022-12-02","current":-10.654132,"twenty":-10.466118,"median":-7.875876,"eighty":-7.603888,"marketCap":102298054},{"date":"2022-12-09","current":-10.121425,"twenty":-10.466118,"median":-7.875876,"eighty":-7.603888,"marketCap":97183151},{"date":"2022-12-16","current":-2.562,"twenty":-10.466118,"median":-7.875876,"eighty":-7.603888,"marketCap":29243788},{"date":"2022-12-23","current":-1.710652,"twenty":-10.466118,"median":-7.875876,"eighty":-7.603888,"marketCap":19526132},{"date":"2022-12-30","current":-1.249174,"twenty":-10.453583,"median":-7.875876,"eighty":-7.603888,"marketCap":14258617},{"date":"2023-01-06","current":-1.281,"twenty":-10.441049,"median":-7.875876,"eighty":-7.580961,"marketCap":14621894},{"date":"2023-01-13","current":-2.752956,"twenty":-10.434782,"median":-7.875876,"eighty":-7.556507,"marketCap":31423450},{"date":"2023-01-20","current":-1.718609,"twenty":-10.434782,"median":-7.875876,"eighty":-7.550393,"marketCap":19616951},{"date":"2023-01-27","current":-1.670869,"twenty":-10.434782,"median":-7.875876,"eighty":-7.550393,"marketCap":19072036},{"date":"2023-02-03","current":-1.933435,"twenty":-10.434782,"median":-7.867968,"eighty":-7.542751,"marketCap":22069070},{"date":"2023-02-10","current":-1.607217,"twenty":-10.424337,"median":-7.867968,"eighty":-7.542751,"marketCap":18345482},{"date":"2023-02-17","current":-1.869782,"twenty":-10.381724,"median":-7.860061,"eighty":-7.536637,"marketCap":21342516},{"date":"2023-02-24","current":-1.702696,"twenty":-10.378397,"median":-7.860061,"eighty":-7.527467,"marketCap":19435313},{"date":"2023-03-03","current":-1.654956,"twenty":-10.357702,"median":-7.860061,"eighty":-4.265844,"marketCap":18890397},{"date":"2023-03-10","current":-1.670869,"twenty":-10.357702,"median":-7.860061,"eighty":-2.418782,"marketCap":19072036},{"date":"2023-03-17","current":-1.400348,"twenty":-10.357702,"median":-7.860061,"eighty":-2.060739,"marketCap":15984182},{"date":"2023-03-24","current":-1.734522,"twenty":-10.357702,"median":-7.852153,"eighty":-1.958179,"marketCap":19798589},{"date":"2023-03-31","current":-1.535609,"twenty":-10.357702,"median":-7.852153,"eighty":-1.869782,"marketCap":17528109},{"date":"2023-04-06","current":-1.400348,"twenty":-10.351494,"median":-7.852153,"eighty":-1.858643,"marketCap":15984182},{"date":"2023-04-14","current":-1.154538,"twenty":-10.347355,"median":-7.852153,"eighty":-1.802948,"marketCap":16305101},{"date":"2023-04-21","current":-1.141492,"twenty":-10.347355,"median":-7.852153,"eighty":-1.755336,"marketCap":16120863},{"date":"2023-04-28","current":-0.327576,"twenty":-10.347355,"median":-7.850967,"eighty":-1.734569,"marketCap":4626227},{"date":"2023-05-05","current":-0.37167,"twenty":-10.347355,"median":-7.844246,"eighty":-1.722141,"marketCap":5248953},{"date":"2023-05-12","current":-0.323359,"twenty":-10.347355,"median":-7.844246,"eighty":-1.702696,"marketCap":4566681},{"date":"2023-05-19","current":-0.244626,"twenty":-10.341146,"median":-7.836338,"eighty":-1.670869,"marketCap":3404726},{"date":"2023-05-26","current":-0.271366,"twenty":-10.337007,"median":-7.836338,"eighty":-1.65973,"marketCap":3776888},{"date":"2023-06-02","current":-0.595797,"twenty":-10.337007,"median":-7.82843,"eighty":-1.607217,"marketCap":8292357},{"date":"2023-06-09","current":-0.579813,"twenty":-10.337007,"median":-7.820523,"eighty":-1.591304,"marketCap":8069879},{"date":"2023-06-16","current":-0.561146,"twenty":-10.337007,"median":-7.603888,"eighty":-1.559478,"marketCap":7810081},{"date":"2023-06-23","current":-0.440415,"twenty":-10.337007,"median":-7.603888,"eighty":-1.529243,"marketCap":6129730},{"date":"2023-06-30","current":-0.430212,"twenty":-10.337007,"median":-7.603888,"eighty":-1.457635,"marketCap":5987729},{"date":"2023-07-07","current":-0.408107,"twenty":-10.332868,"median":-7.603888,"eighty":-1.400348,"marketCap":5680059},{"date":"2023-07-14","current":-0.425111,"twenty":-10.32666,"median":-7.603888,"eighty":-1.296913,"marketCap":5916728},{"date":"2023-07-21","current":-0.368996,"twenty":-10.32666,"median":-7.603888,"eighty":-1.261904,"marketCap":5135720},{"date":"2023-07-28","current":-0.313371,"twenty":-10.32666,"median":-7.603888,"eighty":-1.163669,"marketCap":4361521},{"date":"2023-08-04","current":-0.309309,"twenty":-10.32666,"median":-7.565677,"eighty":-1.141492,"marketCap":4304983},{"date":"2023-08-11","current":-0.307181,"twenty":-10.32666,"median":-7.558035,"eighty":-1.11801,"marketCap":4275368},{"date":"2023-08-18","current":-0.303699,"twenty":-10.32666,"median":-7.550393,"eighty":-1.058,"marketCap":4226907},{"date":"2023-08-25","current":-0.051589,"twenty":-10.32666,"median":-7.550393,"eighty":-0.57554,"marketCap":4665022},{"date":"2023-09-01","current":-0.048582,"twenty":-10.32666,"median":-7.550393,"eighty":-0.562665,"marketCap":4393153},{"date":"2023-09-08","current":-0.041989,"twenty":-10.32666,"median":-7.542751,"eighty":-0.558863,"marketCap":3796895},{"date":"2023-09-15","current":-0.060169,"twenty":-10.320451,"median":-7.542751,"eighty":-0.517114,"marketCap":5440931},{"date":"2023-09-22","current":-0.052281,"twenty":-10.316312,"median":-7.542751,"eighty":-0.441231,"marketCap":4727605},{"date":"2023-09-29","current":-0.060153,"twenty":-10.303896,"median":-7.542751,"eighty":-0.431743,"marketCap":5439425},{"date":"2023-10-06","current":-0.062896,"twenty":-10.295618,"median":-7.542751,"eighty":-0.424227,"marketCap":5687462},{"date":"2023-10-13","current":-0.06304,"twenty":-10.253773,"median":-7.535109,"eighty":-0.407903,"marketCap":5700517},{"date":"2023-10-20","current":-0.061644,"twenty":-10.163206,"median":-7.527467,"eighty":-0.38615,"marketCap":5574322},{"date":"2023-10-27","current":-0.055581,"twenty":-10.142315,"median":-7.523646,"eighty":-0.376992,"marketCap":5026028},{"date":"2023-11-03","current":-0.046534,"twenty":-8.35029,"median":-4.265844,"eighty":-0.362186,"marketCap":4207939},{"date":"2023-11-10","current":-0.035803,"twenty":-7.907506,"median":-2.657478,"eighty":-0.333478,"marketCap":3237545},{"date":"2023-11-17","current":-0.036701,"twenty":-7.907506,"median":-2.17213,"eighty":-0.328592,"marketCap":3289764},{"date":"2023-11-24","current":-0.040004,"twenty":-7.907506,"median":-2.068696,"eighty":-0.324245,"marketCap":3585846},{"date":"2023-12-01","current":-0.031557,"twenty":-7.898017,"median":-2.024935,"eighty":-0.316333,"marketCap":2828641},{"date":"2023-12-08","current":-0.015952,"twenty":-7.891691,"median":-1.958179,"eighty":-0.309502,"marketCap":1429861},{"date":"2023-12-15","current":-0.01023,"twenty":-7.891691,"median":-1.901609,"eighty":-0.307413,"marketCap":916976},{"date":"2023-12-22","current":-0.048692,"twenty":-7.886946,"median":-1.861826,"eighty":-0.30211,"marketCap":4364571},{"date":"2023-12-29","current":-0.055512,"twenty":-7.883783,"median":-1.857848,"eighty":-0.290163,"marketCap":4975946},{"date":"2024-01-05","current":-0.052962,"twenty":-7.883783,"median":-1.853869,"eighty":-0.285597,"marketCap":4747336},{"date":"2024-01-12","current":-0.047393,"twenty":-7.883783,"median":-1.802152,"eighty":-0.251536,"marketCap":4248168},{"date":"2024-01-19","current":-0.034922,"twenty":-7.879039,"median":-1.770326,"eighty":-0.072424,"marketCap":3130284},{"date":"2024-01-26","current":-0.038707,"twenty":-7.875876,"median":-1.750753,"eighty":-0.065177,"marketCap":3469529},{"date":"2024-02-02","current":-0.034243,"twenty":-7.875876,"median":-1.742518,"eighty":-0.062982,"marketCap":3069461},{"date":"2024-02-09","current":-0.03412,"twenty":-7.875876,"median":-1.734522,"eighty":-0.061606,"marketCap":3058450},{"date":"2024-02-16","current":-0.03374,"twenty":-7.875876,"median":-1.721553,"eighty":-0.060163,"marketCap":3024368},{"date":"2024-02-23","current":-0.036285,"twenty":-7.875876,"median":-1.710652,"eighty":-0.059241,"marketCap":3252454},{"date":"2024-03-01","current":-0.064345,"twenty":-7.875876,"median":-1.702696,"eighty":-0.0586,"marketCap":5767693},{"date":"2024-03-08","current":-0.080782,"twenty":-7.875876,"median":-1.674847,"eighty":-0.059241,"marketCap":7241014},{"date":"2024-03-15","current":-0.06769,"twenty":-7.875876,"median":-1.670869,"eighty":-0.060042,"marketCap":6067487},{"date":"2024-03-22","current":-0.069477,"twenty":-7.875876,"median":-1.658934,"eighty":-0.060153,"marketCap":6227737},{"date":"2024-03-28","current":-0.060072,"twenty":-7.875876,"median":-1.619152,"eighty":-0.060088,"marketCap":5904958},{"date":"2024-04-05","current":-0.057206,"twenty":-7.875876,"median":-1.599261,"eighty":-0.058057,"marketCap":5623190},{"date":"2024-04-12","current":-0.057947,"twenty":-7.875876,"median":-1.591304,"eighty":-0.057773,"marketCap":5696100},{"date":"2024-04-19","current":-0.048367,"twenty":-7.875876,"median":-1.559478,"eighty":-0.05663,"marketCap":4754345},{"date":"2024-04-26","current":-0.046937,"twenty":-7.875876,"median":-1.533619,"eighty":-0.055531,"marketCap":4613841},{"date":"2024-05-03","current":-0.044349,"twenty":-7.875876,"median":-1.495826,"eighty":-0.054896,"marketCap":4359415},{"date":"2024-05-10","current":-0.040795,"twenty":-7.875876,"median":-1.424376,"eighty":-0.05319,"marketCap":4010054},{"date":"2024-05-17","current":-0.037826,"twenty":-7.875876,"median":-1.400348,"eighty":-0.051973,"marketCap":3691072},{"date":"2024-05-24","current":-0.03339,"twenty":-7.875876,"median":-1.308848,"eighty":-0.051476,"marketCap":3258245},{"date":"2024-05-31","current":-0.031755,"twenty":-7.875876,"median":-1.292934,"eighty":-0.050906,"marketCap":3098678},{"date":"2024-06-07","current":-0.03697,"twenty":-7.875876,"median":-1.281,"eighty":-0.049989,"marketCap":3607530},{"date":"2024-06-14","current":-0.041742,"twenty":-7.875876,"median":-1.23334,"eighty":-0.049025,"marketCap":4073207},{"date":"2024-06-21","current":-0.041325,"twenty":-7.875876,"median":-1.167583,"eighty":-0.048602,"marketCap":4032547},{"date":"2024-06-28","current":-0.030973,"twenty":-7.875876,"median":-1.16106,"eighty":-0.048367,"marketCap":3022323},{"date":"2024-07-05","current":-0.030887,"twenty":-7.875876,"median":-1.141492,"eighty":-0.047431,"marketCap":3013974},{"date":"2024-07-12","current":-0.043208,"twenty":-7.875876,"median":-1.134969,"eighty":-0.046921,"marketCap":4216224},{"date":"2024-07-15","current":-0.041924,"twenty":-7.875876,"median":-1.128446,"eighty":-0.046855,"marketCap":4090990},{"date":"2024-08-02","current":-0.029261,"twenty":-7.875876,"median":-1.128446,"eighty":-0.046715,"marketCap":2855344},{"date":"2024-08-09","current":-0.025753,"twenty":-7.875876,"median":-1.108878,"eighty":-0.04506,"marketCap":2513036},{"date":"2024-08-16","current":-0.142372,"twenty":-7.875876,"median":-1.069741,"eighty":-0.045348,"marketCap":3108171},{"date":"2024-08-23","current":-0.142372,"twenty":-7.874294,"median":-0.579813,"eighty":-0.045816,"marketCap":3108171},{"date":"2024-08-30","current":-0.130115,"twenty":-7.867968,"median":-0.574291,"eighty":-0.046563,"marketCap":2840580},{"date":"2024-09-06","current":-0.132,"twenty":-7.867968,"median":-0.567606,"eighty":-0.04668,"marketCap":2881748},{"date":"2024-09-13","current":-0.105129,"twenty":-7.867968,"median":-0.561146,"eighty":-0.046855,"marketCap":2295107},{"date":"2024-09-20","current":-0.107014,"twenty":-7.867968,"median":-0.545154,"eighty":-0.046937,"marketCap":2336274},{"date":"2024-09-27","current":-0.108429,"twenty":-7.867968,"median":-0.494999,"eighty":-0.04713,"marketCap":2367150},{"date":"2024-10-04","current":-0.111201,"twenty":-7.860061,"median":-0.442115,"eighty":-0.047393,"marketCap":2427682},{"date":"2024-10-11","current":-0.11563,"twenty":-7.860061,"median":-0.437694,"eighty":-0.04744,"marketCap":2524360},{"date":"2024-10-18","current":-0.111201,"twenty":-7.860061,"median":-0.431488,"eighty":-0.047955,"marketCap":2427682},{"date":"2024-10-25","current":-0.101853,"twenty":-7.860061,"median":-0.426981,"eighty":-0.048002,"marketCap":2223585},{"date":"2024-10-31","current":-0.098959,"twenty":-7.860061,"median":-0.4229,"eighty":-0.048294,"marketCap":2160422},{"date":"2024-11-08","current":-0.07479,"twenty":-7.860061,"median":-0.412358,"eighty":-0.048539,"marketCap":1632777},{"date":"2024-11-15","current":-0.055601,"twenty":-7.860061,"median":-0.407596,"eighty":-0.048609,"marketCap":1213841},{"date":"2024-11-22","current":-0.057411,"twenty":-7.860061,"median":-0.384846,"eighty":-0.048677,"marketCap":1224583},{"date":"2024-11-29","current":-0.118021,"twenty":-7.860061,"median":-0.371269,"eighty":-0.048708,"marketCap":2517426},{"date":"2024-12-06","current":-0.113252,"twenty":-7.860061,"median":-0.366321,"eighty":-0.048948,"marketCap":2415688},{"date":"2024-12-13","current":-0.118692,"twenty":-7.860061,"median":-0.339908,"eighty":-0.049263,"marketCap":2531726},{"date":"2024-12-20","current":-0.136276,"twenty":-7.860061,"median":-0.332663,"eighty":-0.049654,"marketCap":2906796},{"date":"2024-12-27","current":-0.135177,"twenty":-7.856898,"median":-0.328846,"eighty":-0.049901,"marketCap":2883354},{"date":"2025-01-03","current":-0.119791,"twenty":-7.852153,"median":-0.327576,"eighty":-0.050145,"marketCap":2555168},{"date":"2025-01-10","current":-0.129682,"twenty":-7.852153,"median":-0.324836,"eighty":-0.050769,"marketCap":2766145},{"date":"2025-01-17","current":-0.148365,"twenty":-7.852153,"median":-0.320528,"eighty":-0.050891,"marketCap":3164657},{"date":"2025-01-24","current":-0.165949,"twenty":-7.852153,"median":-0.316323,"eighty":-0.050891,"marketCap":3539728},{"date":"2025-01-31","current":-0.151662,"twenty":-7.852153,"median":-0.310469,"eighty":-0.050903,"marketCap":3234983},{"date":"2025-02-07","current":-0.135726,"twenty":-7.852153,"median":-0.309502,"eighty":-0.051217,"marketCap":2895075},{"date":"2025-02-14","current":-0.14287,"twenty":-7.852153,"median":-0.307568,"eighty":-0.05144,"marketCap":3047448},{"date":"2025-02-21","current":-0.134078,"twenty":-7.852153,"median":-0.304393,"eighty":-0.051476,"marketCap":2859913},{"date":"2025-02-28","current":-0.128583,"twenty":-7.852153,"median":-0.301891,"eighty":-0.051476,"marketCap":2742703},{"date":"2025-03-07","current":-0.097811,"twenty":-7.852153,"median":-0.288309,"eighty":-0.051544,"marketCap":2086329},{"date":"2025-03-14","current":-0.08803,"twenty":-7.852153,"median":-0.285224,"eighty":-0.051753,"marketCap":1877696},{"date":"2025-03-21","current":-0.07704,"twenty":-7.852153,"median":-0.271366,"eighty":-0.051882,"marketCap":1643277},{"date":"2025-03-28","current":-0.076919,"twenty":-7.851441,"median":-0.246413,"eighty":-0.052127,"marketCap":1640699},{"date":"2025-04-04","current":-0.166148,"twenty":-7.850967,"median":-0.166148,"eighty":-0.052638,"marketCap":1564028},{"date":"2025-04-11","current":-0.210427,"twenty":-7.846934,"median":-0.172378,"eighty":-0.052911,"marketCap":1980845},{"date":"2025-04-17","current":-0.194413,"twenty":-7.844246,"median":-0.202243,"eighty":-0.052945,"marketCap":1830092},{"date":"2025-04-25","current":-0.195095,"twenty":-7.844246,"median":-0.193158,"eighty":-0.053044,"marketCap":1836513},{"date":"2025-05-02","current":-0.238005,"twenty":-7.844246,"median":-0.194754,"eighty":-0.053214,"marketCap":2240443},{"date":"2025-05-09","current":-0.219626,"twenty":-7.844246,"median":-0.210427,"eighty":-0.053454,"marketCap":2067433},{"date":"2025-05-16","current":-0.209957,"twenty":-7.844246,"median":-0.210015,"eighty":-0.053777,"marketCap":1856780},{"date":"2025-05-23","current":-0.222112,"twenty":-7.841083,"median":-0.211936,"eighty":-0.054087,"marketCap":1964278},{"date":"2025-05-30","current":-0.26967,"twenty":-7.836338,"median":-0.212746,"eighty":-0.054418,"marketCap":2384859},{"date":"2025-06-06","current":-0.348255,"twenty":-7.836338,"median":-0.216817,"eighty":-0.054599,"marketCap":3079838},{"date":"2025-06-13","current":-0.393217,"twenty":-7.836338,"median":-0.221007,"eighty":-0.054896,"marketCap":3477462},{"date":"2025-06-20","current":-0.372436,"twenty":-7.836338,"median":-0.2251,"eighty":-0.05505,"marketCap":3293684},{"date":"2025-06-27","current":-0.366714,"twenty":-7.836338,"median":-0.232735,"eighty":-0.055459,"marketCap":3243086},{"date":"2025-07-03","current":-0.361641,"twenty":-7.823686,"median":-0.234525,"eighty":-0.055501,"marketCap":3198215},{"date":"2025-07-11","current":-0.325132,"twenty":-7.820523,"median":-0.238005,"eighty":-0.055517,"marketCap":2875343},{"date":"2025-07-16","current":-0.302538,"twenty":-7.733869,"median":-0.246413,"eighty":-0.055543,"marketCap":2675531}],"updateTime":1752778657509}}}